Template:Anticoagulation in atrial fibrillation - Revision history

Ostermayer: Marked this version for translation

2026-01-23T09:11:42Z

Marked this version for translation

← Revisión anterior		Revisión del 09:11 23 ene 2026
Línea 2:		Línea 2:
	<translate>		<translate>

	===[[Special:MyLanguage/Anticoagulation\|Anticoagulation]] Therapy===		===[[Special:MyLanguage/Anticoagulation\|Anticoagulation]] Therapy=== <!--T:1-->

			<!--T:2-->
	*'''ACCP Recommendations'''		*'''ACCP Recommendations'''
	**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as [[Special:MyLanguage/warfarin\|warfarin]] [[Special:MyLanguage/EBQ:Evidence_Levels\|(Grade 1A)]], or as [[Special:MyLanguage/aspirin\|aspirin]], at a dose of 75-325 mg/d ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>		**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as [[Special:MyLanguage/warfarin\|warfarin]] [[Special:MyLanguage/EBQ:Evidence_Levels\|(Grade 1A)]], or as [[Special:MyLanguage/aspirin\|aspirin]], at a dose of 75-325 mg/d ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>
	**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1A]]).<ref name="ACCP"></ref>		**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1A]]).<ref name="ACCP"></ref>

			<!--T:3-->
	*'''CCS Recommendations'''		*'''CCS Recommendations'''
	**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral [[Special:MyLanguage/anticoagulants\|anticoagulants]] (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>		**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral [[Special:MyLanguage/anticoagulants\|anticoagulants]] (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>
	</translate>		</translate>

Ostermayer at 09:09, 23 January 2026

2026-01-23T09:09:11Z

← Revisión anterior		Revisión del 09:09 23 ene 2026
Línea 1:		Línea 1:
	<languages/>		<noinclude><languages/></noinclude>
	<translate>		<translate>

Ostermayer: Prepared the page for translation

2026-01-23T09:08:55Z

Prepared the page for translation

← Revisión anterior		Revisión del 09:08 23 ene 2026
Línea 1:		Línea 1:
	===[[Anticoagulation]] Therapy===		<languages/>
			<translate>

			===[[Special:MyLanguage/Anticoagulation\|Anticoagulation]] Therapy===

	*'''ACCP Recommendations'''		*'''ACCP Recommendations'''
	**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as [[warfarin]] [[EBQ:Evidence_Levels\|(Grade 1A)]], or as [[aspirin]], at a dose of 75-325 mg/d ([[EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>		**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as [[Special:MyLanguage/warfarin\|warfarin]] [[Special:MyLanguage/EBQ:Evidence_Levels\|(Grade 1A)]], or as [[Special:MyLanguage/aspirin\|aspirin]], at a dose of 75-325 mg/d ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>
	**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[EBQ:Evidence_Levels\|Grade 1A]]).<ref name="ACCP"></ref>		**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[Special:MyLanguage/EBQ:Evidence_Levels\|Grade 1A]]).<ref name="ACCP"></ref>

	*'''CCS Recommendations'''		*'''CCS Recommendations'''
	**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral [[anticoagulants]] (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>		**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral [[Special:MyLanguage/anticoagulants\|anticoagulants]] (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>
			</translate>

ClaireLewis at 17:35, 19 September 2019

2019-09-19T17:35:47Z

← Revisión anterior		Revisión del 17:35 19 sep 2019
Línea 1:		Línea 1:
	===Anticoagulation Therapy===		===[[Anticoagulation]] Therapy===
	*'''ACCP Recommendations'''		*'''ACCP Recommendations'''
	**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as warfarin [[EBQ:Evidence_Levels\|(Grade 1A)]], or as aspirin, at a dose of 75-325 mg/d ([[EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>		**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as [[warfarin]] [[EBQ:Evidence_Levels\|(Grade 1A)]], or as [[aspirin]], at a dose of 75-325 mg/d ([[EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>
	**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[EBQ:Evidence_Levels\|Grade 1A]]).<ref name="ACCP"></ref>		**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[EBQ:Evidence_Levels\|Grade 1A]]).<ref name="ACCP"></ref>

	*'''CCS Recommendations'''		*'''CCS Recommendations'''
	**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral anticoagulants (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>		**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral [[anticoagulants]] (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>

Rossdonaldson1 at 05:17, 20 March 2016

2016-03-20T05:17:27Z

← Revisión anterior		Revisión del 05:17 20 mar 2016
Línea 1:		Línea 1:
			===Anticoagulation Therapy===
	*'''ACCP Recommendations'''		*'''ACCP Recommendations'''
	**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as warfarin [[EBQ:Evidence_Levels\|(Grade 1A)]], or as aspirin, at a dose of 75-325 mg/d ([[EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>		**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as warfarin [[EBQ:Evidence_Levels\|(Grade 1A)]], or as aspirin, at a dose of 75-325 mg/d ([[EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>

Ostermayer at 15:29, 26 January 2015

2015-01-26T15:29:00Z

← Revisión anterior		Revisión del 15:29 26 ene 2015
Línea 1:		Línea 1:
	*'''ACCP Recommendations'''		*'''ACCP Recommendations'''
	**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as warfarin [[EBQ:Evidence_Levels\|(Grade 1A)]], or as aspirin, at a dose of 75-325 mg/d ([[EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>		**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[EBQ:Evidence_Levels\|Grade 1A]]), either as anticoagulation with an oral VKA, such as warfarin [[EBQ:Evidence_Levels\|(Grade 1A)]], or as aspirin, at a dose of 75-325 mg/d ([[EBQ:Evidence_Levels\|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>
	**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[[[EBQ:Evidence_Levels\|Grade 1A]]).<ref name="ACCP"></ref>		**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[EBQ:Evidence_Levels\|Grade 1A]]).<ref name="ACCP"></ref>

	*'''CCS Recommendations'''		*'''CCS Recommendations'''
	**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral anticoagulants (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>		**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral anticoagulants (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>

Ostermayer: Created page with "*'''ACCP Recommendations''' **In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antit..."

2015-01-26T15:28:28Z

Created page with "*'''ACCP Recommendations''' **In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antit..."

Página nueva

*'''ACCP Recommendations'''
**In patients with AF, including those with paroxysmal AF, with only one of the risk factors listed immediately above, we recommend long-term antithrombotic therapy ([[EBQ:Evidence_Levels|Grade 1A]]), either as anticoagulation with an oral VKA, such as warfarin [[EBQ:Evidence_Levels|(Grade 1A)]], or as aspirin, at a dose of 75-325 mg/d ([[EBQ:Evidence_Levels|Grade 1B]])<ref name="ACCP">Singer DE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):546S-592S</ref>
**In patients with AF, including those with paroxysmal AF, who have two or more of the risk factors we recommend long-term anticoagulation with an oral VKA ([[[[EBQ:Evidence_Levels|Grade 1A]]).<ref name="ACCP"></ref>

*'''CCS Recommendations'''
**Oral anticoagulants are recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65). Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting oral anticoagulants (i.e. NOACs, for non-valvular AF). The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.<ref>Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Canadian Journal of Cardiology 30 (2014) 1114e1130</ref>